Interleukin-15 receptor α (IL-15R) α) is a high affinity IL-15 binding protein that is crucial for mediating IL-15 function. Specifically, IL-15 and IL-2 promote the survival of memory CD8+T cells and regulatory T cells, respectively. Besides, IL-15 is a pro-inflammatory cytokine that has multiple functions at the interface between innate and adaptive immunity. It plays a role in the immune pathogenesis of many inflammatory, infectious, and autoimmune diseases. Moreover, IL-15 also enhances the phagocytic activity of macrophages and neutrophils and inhibits neutrophil apoptosis. Furthermore, bladder cancer is the most common malignant tumor of male and female urinary system. Antibiotics can prevent (AP) to prevent postoperative urinary tract infections (UTI). Here, we will introduce an IL-15 superagonist complex, Inbakicept, and an antibiotic for bladder cancer/infections research, Nogapendekin alfa inbakicept.

Nogapendekin alfa inbakicept is an Antibiotic for Bladder Cancer/Infections Research.

First of all, Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Meanwhile, Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio.

In the second place, N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). Nonetheless, N-803 also increases degranulation and IFNγ production in cells.

Last but not the least, Inbakicept with 0.01-1 nM enhances human NK cell cytotoxicity and increases cytotoxic effector molecule expression. Particularly, Inbakicept enhances rituximab-directed protection from a lethal Daudi lymphoma challenge in mouse model.

All in all, Nogapendekin alfa inbakicept is an antibiotic for bladder cancer/infections research.


[1] Rosario M, et al. Clin Cancer Res. 2016 Feb 1;22(3):596-608.